Mobile Application for Gastroesophageal Reflux Disease
Effectiveness of a Mobile Application in Reducing Symptom Recurrence and Improving Quality of Life and Sleep Quality in Patients With Gastroesophageal Reflux Disease
1 other identifier
interventional
90
1 country
1
Brief Summary
Gastroesophageal reflux disease (GERD) is a chronic condition with frequent symptom recurrence that may negatively affect sleep quality and quality of life. This randomized controlled study aims to evaluate whether a mobile application developed as a mobile application, combined with standard education and diaphragmatic breathing training, can reduce symptom recurrence and improve sleep quality and quality of life in patients with GERD. Participants will be randomly assigned to either an intervention group receiving the mobile application or a control group receiving standard education. Outcomes will be assessed using the GerdQ, Reflux Symptom Index (RSI), GERD-HRQL, and Insomnia Severity Index (ISI) at baseline, 2 weeks, 4 weeks, and 8 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 16, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 16, 2026
CompletedFirst Submitted
Initial submission to the registry
July 30, 2026
CompletedFirst Posted
Study publicly available on registry
August 4, 2026
CompletedAugust 5, 2026
July 1, 2026
5 months
July 30, 2026
August 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
GERD Symptom severity
Change from baseline in gastroesophageal reflux disease symptom severity measured using the GerdQ questionnaire and the Reflux Symptom Index (RSI). The GerdQ total score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms. The RSI total score ranges from 0 to 45, with higher scores indicating more severe reflux symptoms.
Baseline, 2 weeks, 4 weeks, and 8 weeks
Secondary Outcomes (2)
GERD-Related Quality of Life
Baseline, 2 weeks, 4 weeks, and 8 weeks
Sleep Quality
Baseline, 2 weeks, 4 weeks, and 8 weeks
Study Arms (2)
Mobile Application + Standard Education
EXPERIMENTALParticipants receive standard education plus a study mobile application that provides GERD education, lifestyle modification guidance, dietary recommendations, diaphragmatic breathing exercises, and reminder messages for 4 weeks.
Standard Education Alone
ACTIVE COMPARATORParticipants receive standard education for gastroesophageal reflux disease without access to the study mobile application.
Interventions
Participants receive a study mobile application providing gastroesophageal reflux disease education, lifestyle modification guidance, dietary recommendations, diaphragmatic breathing exercises, and reminder messages for 4 weeks.
Participants receive standard education for gastroesophageal reflux disease.
Eligibility Criteria
You may qualify if:
- Age 18 to 60 years.
- Able to communicate in Mandarin Chinese or Taiwanese.
- Owns and is able to use a smartphone.
- Endoscopically confirmed gastroesophageal reflux disease with Los Angeles (LA) Classification Grade B, C, or D erosive esophagitis, or Barrett's esophagus.
- Able and willing to provide written informed consent.
You may not qualify if:
- Previous esophageal or gastric surgery, including anti-reflux surgery.
- Regular use of proton pump inhibitors within the previous 8 weeks.
- Receiving antithrombotic therapy.
- Diabetes mellitus requiring treatment (HbA1c ≥ 6.5%).
- Liver cirrhosis (Child-Pugh class B or higher).
- Chronic kidney disease stage 3 or higher.
- Neurological disorders affecting participation.
- Malignancy other than early-stage cancer.
- Hiatal hernia larger than 2 cm.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Yuan's General Hospital
Kaohsiung City, 80249, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yi-Hsuan Liu, Nurse Practitioner
Fooyin University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Nurse Practitioner
Study Record Dates
First Submitted
July 30, 2026
First Posted
August 4, 2026
Study Start
September 15, 2025
Primary Completion
February 16, 2026
Study Completion
February 16, 2026
Last Updated
August 5, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared because data sharing was not included in the study protocol or informed consent.